Global Hormone Replacement Therapy Research Report 2024: A $35+ Billion Market by 2032 - Industry Trends, Share, Growth, Insight, Top Companies
May 24, 2024 07:48 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Global Hormone Replacement Therapy Market, Size, Forecast 2024-2032, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies...
Veru to Present at the Jefferies Global Healthcare Conference
May 22, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Novo Nordisk A/S - share repurchase programme
May 17, 2024 10:20 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
May 15, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 15, 2024 07:23 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
May 14, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
May 13, 2024 11:49 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 08, 2024 11:31 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
May 08, 2024 06:30 ET
|
Veru Inc.
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific...
Anti-Obesity Drugs Global Strategic Business Report 2024: Market to Reach $4.8 Billion by 2030 - Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth
May 07, 2024 10:41 ET
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Anti-Obesity Drugs Market to...